News

Vaccine Biopharm and ImmuneOnco signed an agreement to study the possibility to combine the CD47 related bispecific antibody with VB2355 and VB6893, two experimental drug developed by Vaccine Biopharm for increased anti-tumor efficacy.
ImmuneOnco Biopharmaceuticals (01541.HK)(Shanghai) Inc. was established in the PRC in June 2015. ImmuneOnco is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. ImmuneOnco is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. Currently approved immunotherapies primarily focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. Harnessing both the innate and adaptive immune systems allows us to overcome the limitations of current T-cell-based immunotherapies and address substantial unmet medical needs of cancer patients.

Prof. Yawei Hua, the distinguished oncologist of Henan Cancer Hospital visited the tumor biology lab of Vaccine Biopharm located in Zhengzhou. Prof. Hua discussed with the research group led by Prof. Zhiqiang Han on the pinpoinst for the treatment of gastrointestinal cancer, and the potential of VB6893 for the gastrointestinal cancer treatment.
VB6893 is a TLR7/8 agonist prodrug, and can be metabolized into the more active form in tumor cells. This drug candidate is currently in preclinical phase and its IND application will be submitted by the end of 2024.